The Latest

Whether you're a patient, clinician, retailer or researcher, come with us as we work to bring quality, accessible cannabis care (and data) to all.

Featured

News

EO Care, Inc. Statement on Cannabinoid Policy Announcements

December 18, 2025

EO Team

The Administration’s decision to move to reclassify cannabis from Schedule I to Schedule III is a watershed moment for adult Americans who currently or might benefit from the responsible use of cannabinoids, especially oncology patients and older adults. It’s a long overdue step that will reduce stigma, open doors for essential research and product development, and increase access to care for patients.

News

EO Data & Methodology: November 2025 Update

At EO, we systematically track how patients feel and function after starting guided cannabis care. The data below come from real people using cannabis to manage symptoms such as pain, sleep disturbance, anxiety, and nausea/vomiting, under the guidance of our clinical protocols.

News

EO Care Releases Latest Cannabinoid-Based Symptom Management Efficacy Data

Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.

News

Twist Out Cancer Turns to EO for Clinically Guided Cannabis Care and Advice for Their Community of Cancer Survivors and Caregivers

40% of cancer patients use cannabis to help the treatment of symptoms. But many are going it alone without clinical guidance, which can be ineffective and even unsafe. That’s why non-profit cancer survivor and caregiver support community Twist Out Cancer is partnering with EO Care...

News

Marijuana as a Schedule III Drug: What Insurers and Employers Need to Know

EBN Talks with Bill Van Faasen, former chairman and CEO of Blue Cross Blue Shield Massachusetts and EO Care board member

News

Upcoming Webinar - Cannabis Use & Employee Health: Guiding Employers on Chronic Illness and Legal Implications

On August 30, 2023, after a scientific/clinical review the US Department of Health and Human Services (HHS) acknowledged that cannabis has medicinal uses and recommended rescheduling cannabis to a Class 3 drug

News

Unlocking Safe and Informed Cannabis Use in the Workplace: What Every Employer Needs to Know

In a recent Benefits Pro article What employers need to know about "guided use" of cannabis by Dr. Brooke Worster, an Associate Professor of Medicine at Jefferson Health in Philadelphia, PA, the Director of the Division of Supportive Oncology, and the Program Director of Cannabis Medicine for the Science and Business Master’s Program...

News

Navigating Cancer Care and Cannabis Use: Transforming Workplace Support

As employers continue to navigate the evolving dynamics of employee cannabis use, Human Resource Executive spoke with Dr. Brooke Worster, an Associate Professor of Medicine at Jefferson Health in Philadelphia, PA, the Director of the Division of Supportive Oncology...

News

Navigating Employee Cannabis Use in the Workplace

eo Care in partnership with HR.com hosted an Employee Cannabis Use – Prevalence, Implications & Solutions webinar for HR professionals where we reviewed the prevalence of cannabis being at an all-time high, the risks of unguided use, and the benefits of employers offering health & wellness support in the form of clinically guided essential cannabis guidance for critical illnesses such as cancer, as well as symptom support, such as pain management, anxiety, and sleeplessness; resulting in improved workforce health, job satisfaction, and increased productivity.

Research

(Part 1) Cannabinoids as a Substitute for Opioids: Basic Science and Clinical Evidence

The lack of pain relief combined with the risk of dangerous side effects, including death, has led to a need for alternative options to help treat chronic pain. Recently, there has been growing interest in the possibility that cannabis may be useful in combination or as a substitute for opioids in people with chronic pain.

Research

(Part 2) Cannabinoids as a Substitute for Opioids: Basic Science and Clinical Evidence

Despite conflicting evidence, for many patients with chronic pain, the risk of using opioids may be greater than the benefits, especially over long periods of time. It is important that patients wishing to understand the potential benefits and risks of using cannabis in addition to opioids discuss this with their health care provider prior to use.

Research

(Part 1) Practical Strategies for Using Medical Cannabis to Reduce Harms Associated With Long-Term Opioid Use

Recent evidence suggests that using medical cannabis in combination with opioids to treat chronic pain may provide better treatment of pain and allow for a lower dose of opioids. It is important we find other tools that can be used to help improve the treatment of pain while keeping patients safe.

Research

(Part 2) Practical Strategies for Using Medical Cannabis to Reduce Harms Associated With Long-Term Opioid Use

Recent studies have shown patients using cannabis combined with opioids may be able to use a lower opioid dose or stop using opioids while still getting pain relief. This can help improve a patient's quality of life while also reducing the risk of serious side effects or death associated with opioids.

Research

(Part 3) Cannabinoids as a Substitute for Opioids: Basic Science and Clinical Evidence

Studies have shown low doses of cannabis may allow for lower doses of opioids to be used, leading to reduced side effects, improved symptoms and improved quality of life. Therefore, the combined use of cannabis and opioids may be a viable option for treating chronic pain in some individuals.

Research

(Part 3) Practical Strategies for Using Medical Cannabis to Reduce Harms Associated With Long-Term Opioid Use

If you are someone using high doses of opioids and not getting adequate pain relief, or you're experiencing unwanted side effects, speaking to your health care provider about a trial of medical cannabis may be an option. Medical cannabis is not right for everyone, just as other medications may not be right for everyone.

The Latest

Featured

EO Care, Inc. Statement on Cannabinoid Policy Announcements

EO Data & Methodology: November 2025 Update

EO Care Releases Latest Cannabinoid-Based Symptom Management Efficacy Data

Twist Out Cancer Turns to EO for Clinically Guided Cannabis Care and Advice for Their Community of Cancer Survivors and Caregivers

Marijuana as a Schedule III Drug: What Insurers and Employers Need to Know

Upcoming Webinar - Cannabis Use & Employee Health: Guiding Employers on Chronic Illness and Legal Implications

Unlocking Safe and Informed Cannabis Use in the Workplace: What Every Employer Needs to Know

Navigating Cancer Care and Cannabis Use: Transforming Workplace Support

Navigating Employee Cannabis Use in the Workplace

(Part 1) Cannabinoids as a Substitute for Opioids: Basic Science and Clinical Evidence

(Part 2) Cannabinoids as a Substitute for Opioids: Basic Science and Clinical Evidence

(Part 1) Practical Strategies for Using Medical Cannabis to Reduce Harms Associated With Long-Term Opioid Use

(Part 2) Practical Strategies for Using Medical Cannabis to Reduce Harms Associated With Long-Term Opioid Use

(Part 3) Cannabinoids as a Substitute for Opioids: Basic Science and Clinical Evidence

(Part 3) Practical Strategies for Using Medical Cannabis to Reduce Harms Associated With Long-Term Opioid Use

EO in Your Inbox